A Phase II study in adult patients with newly diagnosed chronic-phase chronic myeloid leukaemia of initial intensified imatinib therapy and sequential dose-escalation followed by treatment with nilotinib in suboptimal responders to determine the rate and duration of major molecular response.

Trial Profile

A Phase II study in adult patients with newly diagnosed chronic-phase chronic myeloid leukaemia of initial intensified imatinib therapy and sequential dose-escalation followed by treatment with nilotinib in suboptimal responders to determine the rate and duration of major molecular response.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms TIDEL-II
  • Most Recent Events

    • 06 Dec 2016 Results of five-year (final) analysis presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Sub-study results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 23 Oct 2015 Results of KIR genotype substudy (n=148) published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top